Premium
Development and validation of a UPLC‐ESI‐MS/MS method for the determination of N‐butylscopolamine in human plasma: Application to a bioequivalence study
Author(s) -
Favreto Wagner Alex Jann,
Pugens Pinto Ana Maria,
Manfio Josélia Larger,
Fiametti Karina Graziella,
Percio Maycon Fernando,
Santos Mauricio Bedim dos
Publication year - 2012
Publication title -
drug testing and analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 54
eISSN - 1942-7611
pISSN - 1942-7603
DOI - 10.1002/dta.403
Subject(s) - bioequivalence , chromatography , human plasma , chemistry , pharmacology , pharmacokinetics , medicine
A sensitive and fast ultra performance liquid chromatography‐electrospray ionization‐tandem mass spectrometry (UPLC‐ESI‐MS/MS) method for measurements of N‐butylscopolamine in plasma was developed and validated. A single protein precipitation was proposed for the clean up of the plasma and N‐methylhomatropine was added as internal standard (IS). The analyses were carried out using a C 18 column and mobile phase of acetonitrile: 5 mM ammonium acetate + 0.1% formic acid (90:10, v/v ). The triple quadrupole mass spectrometer equipped with an electrospray source in positive mode, was set up in selective reaction monitoring, to detect precursor → product ion 360.0 → 194.0 m/z and 290.3 → 138.0 m/z transitions, for N‐butylscopolamine and IS, respectively. The method was linear in 0.03 (lower limit of quantitation; LLOQ) – 10.00 ng/ml range for N‐butylscopolamine. Satisfactory selectivity, linearity, precision, accuracy, and robustness were obtained for the UPLC‐ESI‐MS/MS method. The proposed method was successfully applied to a pharmacokinetic study of healthy human volunteers; the results showed that the two scopolamine butylbromide formulations tested are not bioequivalent in rate and extent of absorption. Copyright © 2012 John Wiley & Sons, Ltd.